The way you think, the way you behave, the way you eat, can influence your life by 30 to 50 years.

-Deepak Chopra

 

PNA Spotlight: Dr. Manish Aghi

This month the PNA Spotlight focuses on Dr. Manish K. Aghi.Dr. Manish Aghi is a neurosurgeon specializing in brain tumors at UCSF Medical Center. He cares for adult patients with a wide range of conditions, including astrocytomas and anaplastic astrocytomas, oligodendrogliomas, glioblastomas, meningiomas and pituitary adenomas. As principal investigator at the UCSF Brain Tumor Research Center, his interests include glioblastoma angiogenesis, mechanisms of glioblastoma resistance to anti-angiogenic therapy and experimental glioblastoma therapies such as cancer-killing viruses.
Professor Aghi earned his medical degree and a doctoral degree in neurosciences from Harvard Medical School. He completed a residency in neurosurgery at Massachusetts General Hospital. He is a member of the Society for Neuro-Oncology, American Association of Neurological Surgeons, Congress of Neurological Surgeons and Pituitary Network Association. Among his honors are the Preuss and Mahaley awards from the American Association of Neurological Surgeons, and the Ronald L. Bittner Award, Synthes Skull Base Award and Integra Foundation Award from the Congress of Neurological Surgeons.
His answers follow.

Read more

PNA Medical Corner: Pituitary Centers of Excellence

This month the PNA Medical Corner focuses on an article co-authored by several members and colleagues of the PNA: Drs. Chanson, Kaiser, Laws, van der Lely, and Melmed. It addresses a topic that PNA has sought to promote for decades: the designation of Pituitary Centers of Excellence, where patients can get highly specialized care

Link: https://pubmed.ncbi.nlm.nih.gov/37640885/

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

Read More

Featured News and Updates

The FDA has approved NGENLA (somatrogon-ghla)

The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

See the Press Release here>

News Articles June 2026

Woman diagnosed with both Cushing’s Disease and Syndrome

An study in Cureus details the rare case of a Moroccan woman diagnosed with both Cushing’s Disease and Cushing’s Syndrome.  She had been self-medicating with dexamethasone. Read more: https://www.cureus.com/articles/494214-is-it-possible-to-have-coexisting-exogenous-and-endogenous-cushings-syndrome#!/

Real Housewife, former beauty queen tells her pituitary story

Kelsey Swanson, a cast member of Real Housewives of Rhode Island and a former Miss Rhode Island discusses her battle with a pituitary tumor in an article in Yahoo.com. Read more: https://www.yahoo.com/entertainment/tv/articles/breaking-down-rhori-kelsey-swanson-150326808.html

Study links radiotherapy to increased mortality in pituitary patients

An article in Medscape looks at a study on radiotherapy in patients with pituitary tumors and found increased mortality rates. Read more: https://www.medscape.com/viewarticle/increased-mortality-after-radiotherapy-pituitary-adenoma-2026a1000gmy

Pituitary mass mistaken for migraine in expectant mother

An article in the Times of India explains the case of a pregnant woman with debilitating headaches and vision loss. Doctors initially thought she had migraines, when it turned out to be a suprasellar mass. Read more: https://timesofindia.indiatimes.com/health/severe-headache-during-pregnancy-turned-out-to-be-a-1-in-9-million-pituitary-disorder-after-symptoms-were-mistaken-for-migraine/articleshow/131293833.cms

 

 

Research Articles

Research Articles June 2026

Pituitary Tumors


Pituitary adenomas associated with hydrocephalus: clinical characteristics, risk stratification, and clinical management.

Zhou W, Yu M, Cheng S, Zhu H, Cao L, Li Z, Liu C, Bai J, Zhao P, Zhang Y, Gui S, Li C.J Neurooncol. 2026 May 29;178(1):31. doi: 10.1007/s11060-026-05653-w.

Organoids as next-generation models for investigating intracranial tumours.

Roy S, Zahin F, Nkrumah-Boateng PA, Chaudhry S, Nassor M, Kwarteng MFA, Owusu-Boampong AB, Wireko AA.Mol Brain. 2026 May 30. doi: 10.1186/s13041-026-01317-y. Online ahead of print.PMID: 42218467 Review.

Enhancing brain tumor classification with a simplified CNN through hyperparameter optimization.

Remzan N, Tahiry K, Farchi A, Arbi A.Biomed Phys Eng Express. 2026 May 29. doi: 10.1088/2057-1976/ae74d5. Online ahead of print.PMID: 42214387

LAT1-mediated amino acid metabolism reprogramming: a novel metabolic vulnerability in recurrent pituitary neuroendocrine tumors.

Pei ZJ, Li GW, Yu JH, Yang HR, Fang Y, Zhou LX.Endocr Connect. 2026 May 29:EC-25-0860. doi: 10.1530/EC-25-0860. Online ahead of print.


Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?

di Filippo L, Acanfora M, Bolamperti S, Terenzi U, Bonomo M, Giustina A.Pituitary. 2026 May 29;29(3):96. doi: 10.1007/s11102-026-01667-9.


The hook effect in macroprolactinomas: tumor size thresholds, prolactin patterns, and clinical consequences – a systematic review.

Yadav P, Hamrahian AH, Salvatori R.Pituitary. 2026 May 29;29(3):98. doi: 10.1007/s11102-026-01705-6.

 

Pituitary Surgery


Systematic anatomical validation of the endoscopic mononostril transethmoid-paraseptal approach to the central skull base.

Eördögh M, Weidemeier M, Baksa G, Patonay L, Simmen D, Schroeder HWS, El Refaee E, Hosemann W, Reisch R, Briner HR.Brain Spine. 2026 May 15;6:106092. doi: 10.1016/j.bas.2026.106092. eCollection 2026.

 

Pituitary apoplexy

Management-specific outcome evaluation of pituitary apoplexy; conservative and surgical approach.

Guijt MC, Verstegen MJT, Zamanipoor Najafabadi AH, Bakker LEH, Notting IC, Pelsma ICM, van Furth WR, Biermasz NR, Claessen KMJA.Pituitary. 2026 May 29;29(3):97. doi: 10.1007/s11102-026-01695-5.

 

Acromegaly

Speckle-tracking echocardiography reveals the synergistic impact of GH/IGF-1 excess and metabolic dysregulation on cardiac dysfunction in acromegaly.

Chen M, Zhang P, He W, Jin J, Huang R, Liao Z, Xiao H, Yao F, Li Y, Li H.Pituitary. 2026 May 29;29(3):95. doi: 10.1007/s11102-026-01684-8.

 

Cushing’s disease

Real-Time PCR-Based Intraoperative Molecular Boundary Diagnosis of Corticotroph Pituitary Neuroendocrine Tumors.

Sato Y, Takeuchi K, Ohka F, Nagata Y, Maeda S, Matsuyama T, Hirose T, Deguchi S, Okumura E, Iwami K, Saito R.J Neurosci Methods. 2026 May 28:110814. doi: 10.1016/j.jneumeth.2026.110814. Online ahead of print.PMID: 42214473

 

Hyperprolactinemia


Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto’s Thyroiditis.

Guimarães GNF.Case Rep Med. 2026 May 27;2026:3016596. doi: 10.1155/carm/3016596. eCollection 2026.

 

Hormonal Health

Genetic Insights Into AVP Deficiency: Identification of a Novel AVP Variant and Compilation of a Curated Catalogue of Pathogenic Variants.

Joseph J, Søndergaard E, Knorr S, Knudsen JH, Rittig S, Christensen JH.Clin Genet. 2026 May 29. doi: 10.1111/cge.70183. Online ahead of print.

 

 

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.